$47.44
0.35% today
Nasdaq, Sep 30, 04:48 pm CET

Supernus Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Supernus Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
73%
Hold
27%

Supernus Pharmaceuticals, Inc. Price Target

Target Price $45.90
Price $47.60
Deviation
Number of Estimates 7
7 Analysts have issued a price target Supernus Pharmaceuticals, Inc. 2026 . The average Supernus Pharmaceuticals, Inc. target price is $45.90. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 8 Analysts recommend Supernus Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Supernus Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Supernus Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 661.82 703.41
8.94% 6.28%
EBITDA Margin 25.47% 13.97%
58.99% 45.14%
Net Margin 11.16% 18.09%
5,037.06% 62.07%

7 Analysts have issued a sales forecast Supernus Pharmaceuticals, Inc. 2025 . The average Supernus Pharmaceuticals, Inc. sales estimate is

$703m
Unlock
. This is
5.76% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$733m 10.19%
Unlock
, the lowest is
$658m 1.08%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $662m 8.94%
2025
$703m 6.28%
Unlock
2026
$831m 18.15%
Unlock
2027
$946m 13.86%
Unlock
2028
$1.0b 10.64%
Unlock
2029
$1.1b 4.30%
Unlock
2030
$1.1b 1.47%
Unlock
2031
$1.2b 4.15%
Unlock
2032
$1.2b 5.11%
Unlock

4 Analysts have issued an Supernus Pharmaceuticals, Inc. EBITDA forecast 2025. The average Supernus Pharmaceuticals, Inc. EBITDA estimate is

$98.3m
Unlock
. This is
31.01% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$237m 66.56%
Unlock
, the lowest is
$-32.6m 122.90%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $169m 73.20%
2025
$98.3m 41.69%
Unlock
2026
$155m 57.45%
Unlock
2027
$236m 52.78%
Unlock
2028
$482m 104.07%
Unlock

EBITDA Margin

2024 25.47% 58.99%
2025
13.97% 45.14%
Unlock
2026
18.62% 33.29%
Unlock
2027
24.98% 34.16%
Unlock
2028
46.08% 84.47%
Unlock

7 Supernus Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Supernus Pharmaceuticals, Inc. net profit estimate is

$127m
Unlock
. This is
97.32% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$136m 111.04%
Unlock
, the lowest is
$119m 84.17%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $73.9m 5,496.21%
2025
$127m 72.29%
Unlock
2026
$139m 9.59%
Unlock
2027
$219m 56.78%
Unlock
2028
$306m 40.05%
Unlock
2029
$386m 26.17%
Unlock
2030
$346m 10.37%
Unlock
2031
$381m 9.92%
Unlock
2032
$458m 20.30%
Unlock

Net Margin

2024 11.16% 5,037.06%
2025
18.09% 62.07%
Unlock
2026
16.78% 7.24%
Unlock
2027
23.11% 37.72%
Unlock
2028
29.25% 26.57%
Unlock
2029
35.38% 20.96%
Unlock
2030
31.26% 11.64%
Unlock
2031
32.99% 5.53%
Unlock
2032
37.75% 14.43%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 1.32 2.27
6,500.00% 71.97%
P/E 20.99
EV/Sales 3.05

7 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast for earnings per share. The average Supernus Pharmaceuticals, Inc. EPS is

$2.27
Unlock
. This is
99.12% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$2.43 113.16%
Unlock
, the lowest is
$2.12 85.96%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $1.32 6,500.00%
2025
$2.27 71.97%
Unlock
2026
$2.49 9.69%
Unlock
2027
$3.90 56.63%
Unlock
2028
$5.46 40.00%
Unlock
2029
$6.89 26.19%
Unlock
2030
$6.17 10.45%
Unlock
2031
$6.78 9.89%
Unlock
2032
$8.16 20.35%
Unlock

P/E ratio

Current 41.75 87.78%
2025
20.99 49.73%
Unlock
2026
19.15 8.77%
Unlock
2027
12.22 36.19%
Unlock
2028
8.72 28.64%
Unlock
2029
6.91 20.76%
Unlock
2030
7.71 11.58%
Unlock
2031
7.02 8.95%
Unlock
2032
5.83 16.95%
Unlock

Based on analysts' sales estimates for 2025, the Supernus Pharmaceuticals, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.23 50.93%
2025
3.05 5.53%
Unlock
2026
2.58 15.36%
Unlock
2027
2.27 12.17%
Unlock
2028
2.05 9.62%
Unlock
2029
1.97 4.12%
Unlock
2030
1.94 1.44%
Unlock
2031
1.86 3.99%
Unlock
2032
1.77 4.86%
Unlock

P/S ratio

Current 4.01 49.24%
2025
3.79 5.44%
Unlock
2026
3.21 15.36%
Unlock
2027
2.82 12.17%
Unlock
2028
2.55 9.62%
Unlock
2029
2.44 4.12%
Unlock
2030
2.41 1.44%
Unlock
2031
2.31 3.99%
Unlock
2032
2.20 4.86%
Unlock

Current Supernus Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Piper Sandler
Locked
Locked
Locked Aug 29 2025
Cantor Fitzgerald
Locked
Locked
Locked Aug 06 2025
Cantor Fitzgerald
Locked
Locked
Locked Feb 26 2025
Cantor Fitzgerald
Locked
Locked
Locked Feb 19 2025
Piper Sandler
Locked
Locked
Locked Sep 11 2024
Analyst Rating Date
Locked
Piper Sandler:
Locked
Locked
Aug 29 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Aug 06 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Feb 26 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Feb 19 2025
Locked
Piper Sandler:
Locked
Locked
Sep 11 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today